Published results of a Chinese gene-editing trial for muscular dystrophy show one of four boys died and the benefit was limited

The stories

12 stories on this beat today.

Every story told the same way: what happened, who is involved, why it matters, how it works, the truth and the good news.

1. 01

   Published results of a Chinese gene-editing trial for muscular dystrophy show one of four boys died and the benefit was limited

   1 of 4

   boys given HuidaGene's gene-editing treatment who died

   an autopsy found a sudden lung failure linked to the treatment [1]

   24 hours

   from his dose to sudden, severe belly pain and fever

   his heart later stopped, and doctors could not revive him [1]

   4

   monkeys tested before the trial began

   too few to reveal a rare reaction, the authors say [1]

   About a year

   between the boy's death and the company announcing it

   HuidaGene announced the death on 5 August [1]

   What happened

   • HuidaGene, a Shanghai gene-editing company, has published its treatment's first trial in people. [1]
   • Four boys with Duchenne muscular dystrophy were given its gene-editing treatment. [1]
   • 1 of the 4 boys died; he had been given a high dose. [1]
   • The treatment edited some of the target genes, but its benefit was limited. [1]
   • The results are now published in Cell, a science journal. [1]
   • The treatment carried a base editor, a kind of CRISPR gene-editing tool, into muscle. [1]
   • It travelled inside AAV, a virus that does not cause disease in people. [1]
   • The editor was meant to correct the faulty gene inside the muscle cells. [1]
   • 2 boys got a low dose and 2 got a high dose. [1]
   • Within 24 hours, the boy had sudden, severe belly pain and then a fever. [1]
   • His blood ran short of oxygen, and his heartbeat turned slow and irregular. [1]
   • His heart stopped, and doctors could not revive him. [1]
   • An autopsy found he died of a sudden lung failure linked to the treatment. [1]
   • A large virus dose is needed to reach muscle all over the body. [1]
   • Such big doses raise the risk of severe immune reactions. [1]
   • Ian Woodcock, a children's nerve doctor in Melbourne, links the boy's fast decline to his dose. [1]
   • 'This amount of foreign invasion really triggers the immune system,' Woodcock says. [1]
   • Each boy's dose was set by his body weight. [1]
   • The boy who died weighed more for his height, so his dose was bigger. [1]
   • But more weight need not mean more muscle, which is what the treatment aims at. [1]
   • The authors now say dosing by body weight may not be right. [1]
   • Before the trial, the team tested both doses in 4 monkeys. [1]
   • The monkeys showed no harmful side effects, only a weak, short immune reaction. [1]
   • The authors say four animals were too few to reveal a rare reaction like the boy's. [1]
   • Hui Yang, a HuidaGene co-founder, says more animals still could not guarantee finding one. [1]

   Who is involved

   Duchenne muscular dystrophy is an inherited disease that mostly affects boys. [1]

   A fault in the DMD gene harms the body's ability to make dystrophin. [1]

   Dystrophin is a protein that strengthens muscle fibres. [1]

   Without enough of it, muscles weaken, walking gets hard, and the disease ends in death. [1]

   • HuidaGene a gene-editing company in Shanghai; it ran the trial in four boys and published the results
   • Ian Woodcock a children's nerve doctor and researcher at Murdoch Children's Research Institute in Melbourne; he links the death to the dose
   • Hui Yang HuidaGene's co-founder and an author of the paper; he says the safeguards were not enough
   • Researchers criticised the long wait

   How it unfolded

   HuidaGene announced the death on 5 August, about a year after it happened. [1]

   Researchers criticised the company for waiting so long to say so. [1]

   HuidaGene says it sent a full report to a journal in January. [1]

   It says it wanted to establish the facts before telling the public. [1]

   1. About a year earlier the boy dies
   2. 5 August HuidaGene announces it
   3. January report sent to a journal
   4. 5 August death made public
   5. About a year before one boy dies after a high dose [1]
   6. January HuidaGene sends a full report to a journal [1]
   7. 5 August HuidaGene announces the death [1]
   8. 27 August HuidaGene tells Nature it wanted the facts first [1]
   9. Now the trial's results are published in Cell [1]

   Why it matters

   Researchers say treatments like this urgently need safe doses worked out. [1]

   Severe immune reactions, including deaths, have also hit other gene therapy trials for Duchenne. [1]

   The death also put China's fast-track rules for clinical trials in the spotlight. [1]

   How it works

   Immunology studies the body's defences, which attack what looks foreign, even a harmless virus. [1]

   The more virus arrives at once, the stronger that attack can be. [1]

   Why a disease from one faulty gene can be treated at four different steps

   Medical geneticists can treat a one-gene disease at four steps: fix the gene, add a working copy, give the missing protein, or help a faulty one work.

   The twist

   Giving the protein is the safer step, but it never ends: Fabry patients need a drip every two weeks. Fixing the gene aims to last, but it must reach cells all over the body, and getting it there is where the danger is.

   Step by step

   1. 1 A gene holds the instructions for one protein
   2. 2 A fault in the gene leaves too little protein, or a misshapen one
   3. 3 Without that protein a job goes undone: muscles weaken, nerves fail, an enzyme stalls
   4. 4 Medicine can step in at the gene: fix it, or add a working copy
   5. 5 Or further along: give the protein itself, or a drug that helps a faulty one work

   The same force, elsewhere today

   Where this chain is also running, in today's other stories.

   • HuidaGene's trial in China

     It worked on the gene itself, sending an editor into muscle, and the big virus dose needed to reach every muscle is suspected in one boy's death.

   • The DNA loops for Friedreich's ataxia

     They add a working copy of the FXN gene without a virus, and in mice frataxin rose 18-fold in the liver.

   • BioMarin's Fabry deal

     Its new drug gives the faulty enzyme from outside as a monthly shot, while its pill Galafold helps a misshapen enzyme do its job.

   • Ivacaftor for scarred lungs

     It helps the CFTR protein work rather than replacing it, tried here in mice with lung scarring.

   Where you've seen this

   Haemophilia

   people can inject the missing clotting protein again and again, or have a gene therapy meant to let the body make it

   Type 1 diabetes

   the body stops making insulin, a protein, so people inject insulin every day instead

   A misprinted manual

   a company can fix the master file once, or keep mailing a corrected page to everyone holding an old copy

   The catch

   This fits diseases where one gene leaves the body short of one protein. Many illnesses come from many genes, or from a protein that does harm by being there, and adding more of it does not help.

   And the whole of it

   The same chain, from gene to protein to job, is running in every reader's body right now. The four boys in China, the families on two-weekly drips and the people with Friedreich's ataxia each meet it at one step, and see little of the rest.

   The truth

   • What is really going on HuidaGene, a Shanghai company, gave a gene editor to four boys with Duchenne muscular dystrophy, and one died after a high dose that was set by his body weight. [1]
   • What is really going on The company told the public about a year after the death, and its own co-founder says the safeguards it used were not enough. [1]
   • The team gave immune-calming drugs and spaced out each boy's dose after a safety review. [1]
   • Yang says those steps were not enough. [1]
   • He says this kind of immune harm 'remains difficult to predict'. [1]
   • Whether the bigger dose caused the reaction is still unclear, he says. [1]
   • Who pays The boy who died, and his family — Doses were set by body weight, so as the heavier high-dose boy he received more of the virus-carried treatment. [1]
   • Nobody knows yet

     What set off the boy's fatal immune reaction.

     He got a bigger dose because he weighed more for his height, but the authors say it is still unclear whether that triggered it. [1]

   What comes next

   Woodcock says new kinds of AAV that enter muscle better could allow smaller doses. [1]

   Or teams could carry the editor without AAV at all. [1]

1. 02

   Ebola deaths in Congo pass 5,000

   What happened

   • Ebola has now killed 5,026 people in Congo, out of 10,351 infected, government data show. [2]
   • Only West Africa's outbreak of 2014 to 2016 killed more: about 11,000 people. [2]
   • Nearly half of those with confirmed Ebola have died: the death rate is 48.6%. [3]
   • It has reached 8 of Congo's 26 provinces. [2]
   • About 80% of new cases come from people nobody was tracking, Africa's disease agency says. [2]
   • A third of the dead died before any test, the World Health Organization says. [2]

   Who is involved

   Ebola is a deadly virus disease, caught by touching a sick person's blood or vomit. [3]

   • Congo's army
   • Armed groups

   How it unfolded

   This outbreak was declared in May and is caused by the Bundibugyo strain. [2]

   There is no approved vaccine or medicine for that strain. [3]

   1. May outbreak declared
   2. Now 5,026 deaths

   Why it matters

   Ituri and North Kivu, two eastern provinces at war, hold 9,782 of the cases. [2]

   Fighting between the army and armed groups there limits where health workers can go. [2]

   How it works

   Epidemiologists, who study how diseases spread, stop outbreaks by tracing every patient's contacts. [2]

   When most new cases come from untraced people, the tracing has fallen behind the virus. [2]

   The truth

   • Health workers face attacks too: a nurse was killed answering an Ebola alert last week. [2]
   • On Friday, staff at an Ebola centre in Tchomia struck over 4 months' unpaid pay. [2]
   • Who pays Ebola workers at Tchomia, in Ituri — They stopped work on Friday after four months without wages, with five confirmed and ten suspected patients in their care. [2]
   • Who pays People in Ituri and North Kivu — Fighting between the army and armed groups keeps health workers out, and the two provinces hold 9,782 of the cases. [2]
   • Nobody knows yet

     How far Ebola is spreading in Congo without anyone seeing it.

     About 80% of new cases come from people outside the watched contacts, and a third of the dead died before any test. [2]

   Good news

   • 2,788 people in Congo have recovered from Ebola since the outbreak was declared in May.
2. 03

   Nigeria tests two suspected Ebola cases

   What happened

   • Nigeria's disease agency said on Saturday it is testing two suspected Ebola cases. [5]
   • The two are in north-east Nigeria and have been isolated. [5]
   • Officials are listing everyone the two met while laboratory tests run. [5]

   Who is involved

   The agency is the Nigeria Centre for Disease Control and Prevention, NCDC. [5]

   How it unfolded

   Nigeria confirmed its first Ebola case in more than a decade last week. [5]

   She was a Swiss woman who had travelled to Uganda, then to Abuja, Nigeria's capital. [5]

   She is being treated at Geneva University Hospital, Swiss authorities say. [6]

   Nigeria released 10 billion naira, about $6.7 million, in emergency funds after her case. [6]

   1. Last week first case in over a decade
   2. Saturday two suspected cases
   3. First Uganda
   4. Then Abuja, Nigeria

   Why it matters

   If confirmed, the two cases could mean Ebola is spreading inside Nigeria. [5]

   How it works

   Epidemiologists keep 'suspected' and 'confirmed' apart: only a laboratory test confirms a case. [6]

   The truth

   • Officials have not said whether the two are linked to the first case. [5]
   • Nobody knows yet

     Whether Nigeria's two suspected cases are Ebola, and how they got it.

     Laboratory tests are still running, and officials have not said whether the two are linked to the Swiss woman who was the first case. [5]

   What comes next

   NCDC says it will give more details when the results are in. [6]

3. 04

   A drug holds back returning bone cancer

   What happened

   • A drug from GSK and Hansoh held back a returning bone cancer longer than chemotherapy did. [7]
   • It enrolled 122 people aged 12 and over whose osteosarcoma, a bone cancer, had returned. [7]
   • They were picked at random to get the drug, ris-rez, or two chemotherapy drugs. [7]
   • On ris-rez, the typical patient went 5.5 months before the cancer grew or they died. [7]
   • On chemotherapy, the typical patient went 1.5 months. [7]
   • GSK puts it as a 67% cut in the risk of the cancer growing or death. [7]

   Who is involved

   Hansoh Pharma, GSK's partner in Shanghai, ran the final-stage trial in China. [7]

   • GSK drug company
   • Hansoh Pharma its partner, Shanghai

   How it unfolded

   Hansoh said in July that the trial had met its main goal, without giving data. [7]

   1. July Hansoh says the goal was met
   2. Now GSK gives the numbers

   Why it matters

   Returning osteosarcoma has no approved drugs and no standard treatment. [7]

   In bone cancer, GSK leads Daiichi Sankyo and Merck, whose rival drug is in early trials. [7]

   How it works

   Ris-rez is an antibody joined to a cancer-killing drug, aimed at a marker called B7-H3. [7]

   Oncologists, cancer doctors, call this progression-free survival: time before the cancer grows. [7]

   The truth

   • 93% of patients on ris-rez had severe side effects, against 83% on chemotherapy. [7]
   • Patients were followed for a typical 7.1 months, and no survival figure was given. [7]
   • Who gains GSK — Its drug has a final-trial result in returning bone cancer while Daiichi Sankyo and Merck have only begun early trials there. [7]
   • Who pays Patients in GSK's bone cancer trial — Nearly all on the new drug had severe side effects, mostly blood problems, and 4% stopped treatment because of them. [7]
   • Nobody knows yet

     Whether ris-rez helps people with returning bone cancer live longer.

     The trial reports how long the cancer was held back after a typical 7.1 months of follow-up, and gives no survival figure. [7]

   Good news

   • In GSK's trial, people whose bone cancer had come back went a typical 5.5 months before it grew again on the new drug, against 1.5 months on chemotherapy.
4. 05

   BioMarin buys a monthly Fabry shot

   What happened

   • BioMarin will pay $70 million up front for rights to a new Fabry disease drug. [8]
   • Up to $405 million more follows if the drug meets goals, plus a share of sales. [8]
   • The Korean drug is a monthly injection under the skin. [8]
   • It is in an early trial in the US, Argentina and South Korea, testing 3 doses. [8]

   Who is involved

   The drug comes from GC Biopharma and Hanmi Pharm, two South Korean companies. [8]

   BioMarin, which bought Amicus Therapeutics for $4.8 billion, already sells a Fabry pill, Galafold. [8]

   Fabry disease comes from gene faults that leave people with a faulty enzyme. [8]

   • GC Biopharma South Korea
   • Hanmi Pharm South Korea
   • Sanofi Fabrazyme
   • Chiesi Elfabrio

   How it unfolded

   The approved drips, Sanofi's Fabrazyme and Chiesi's Elfabrio, are given every 2 weeks. [8]

   Why it matters

   If it works, people with Fabry could swap drips every two weeks for monthly shots. [8]

   It could also help people whose gene faults Galafold does not suit. [8]

   How it works

   Medicine can replace a faulty enzyme by giving the working protein from outside. [8]

   Galafold works differently: it holds certain misshapen enzymes steady so they reach their place. [8]

   Its new drug gives the faulty enzyme from outside as a monthly shot, while its pill Galafold helps a misshapen enzyme do its job.

   The idea, in story 01: Why a disease from one faulty gene can be treated at four different steps →

   The truth

   • BioMarin hopes Galafold alone will reach about $1.4 billion a year in sales by the mid-2030s. [8]
   • Whether the shot works is unknown: the trial measures kidney health for up to 48 weeks. [8]
   • Who gains GC Biopharma and Hanmi Pharm — BioMarin pays them $70 million now and up to $405 million later, and they keep the right to sell the drug in South Korea. [8]
   • Who gains BioMarin — A monthly shot would let it compete with Sanofi's and Chiesi's two-weekly drips, beside its own pill. [8]
   • Who pays People with Fabry disease today — The approved drips go into a vein every two weeks, and Galafold suits only some gene faults. [8]
   • Nobody knows yet

     Whether the monthly Fabry shot works in people.

     It is in an early trial of three doses, with kidney results measured over up to 48 weeks. [8]

5. 06

   DNA loops raise a missing protein in mice

   What happened

   • A Karolinska Institutet team in Stockholm raised frataxin, a protein patients lack, in mice. [9]
   • The team used minicircles: small loops of DNA that carry a gene without a virus. [9]
   • In skin cells from patients, frataxin rose to the level seen in healthy cells. [9]
   • In mice, frataxin rose 18-fold in the liver and 3-fold in the heart. [9]

   Who is involved

   Frataxin runs low in Friedreich's ataxia, an inherited disease that slowly damages nerves. [9]

   It is the most common inherited ataxia among Europeans, affecting about 1 in 29,000. [9]

   Ataxia means losing control of movement; the disease harms the brain area that coordinates it. [9]

   How it unfolded

   A repeated stretch of DNA in the FXN gene leaves cells with too little frataxin. [9]

   Frataxin helps mitochondria, the cell's power units, make energy. [9]

   Why it matters

   HuidaGene carried its editor in a virus, and the virus dose is suspected in a death. [1]

   Minicircles carry no virus at all, and the authors call them safer than older DNA carriers. [9]

   How it works

   Gene therapy adds a working copy of a gene so cells can make the missing protein. [9]

   They add a working copy of the FXN gene without a virus, and in mice frataxin rose 18-fold in the liver.

   The idea, in story 01: Why a disease from one faulty gene can be treated at four different steps →

   The truth

   • This study treated cells and mice, not people. [9]
   • The mice got the DNA by a high-pressure injection into a tail vein. [9]
   • Nobody knows yet

     Whether the DNA loops or ivacaftor will help any patient.

     Both results so far come from cells and mice. [9][10]

   Good news

   • In skin cells from people with Friedreich's ataxia, small loops of DNA raised the missing protein, frataxin, to the level of healthy cells.
6. 07

   Ivacaftor eases scarred lungs in mice

   What happened

   • Ivacaftor, a drug that helps the CFTR protein work, reduced lung scarring in mice. [10]
   • In mice, the drug limited the build-up of collagen, a tough protein found in scars. [10]
   • It also restored the lungs' structure and how well they worked. [10]
   • When CFTR was removed from those cells, the drug worked less well. [10]

   Who is involved

   CFTR is a protein whose full name comes from cystic fibrosis. [10]

   The disease studied is pulmonary fibrosis, a deadly illness in which the lungs scar. [10]

   The team was at the University of Alabama at Birmingham, with Ningxia University in China. [10]

   • University of Alabama at Birmingham US
   • Ningxia University China

   How it unfolded

   Lungs of people with the disease hold less CFTR, the authors note. [10]

   Ageing of one kind of air-sac cell is a major driver of the scarring. [10]

   Why it matters

   That points to the drug working through CFTR itself, the authors say. [10]

   How it works

   Pharmacologists call such a drug a potentiator: it helps a protein do its job better. [10]

   It helps the CFTR protein work rather than replacing it, tried here in mice with lung scarring.

   The idea, in story 01: Why a disease from one faulty gene can be treated at four different steps →

   The truth

   • The mice's scarring was caused on purpose by a drug, bleomycin, not by the disease. [10]
   • Grants from China's national science foundation paid for the work. [10]
7. 08

   Drug industry feels better about the FDA

   What happened

   • Drug-industry insiders feel better about the FDA, the US drug regulator, a survey of 569 found. [11]
   • Its score for regulation rose to 75, from 50 the quarter before. [11]
   • A year ago, it was 23. [11]
   • Among investors, 40% now call the climate more supportive than a year ago. [11]
   • But 58% of people at big drug companies still say regulation is getting worse. [11]

   Who is involved

   Endpoints News, a drug-industry news site, ran the survey for July to September. [11]

   • Kyle Diamantas acting FDA head
   • Heidi Overton nominee, waiting for a vote

   How it unfolded

   It is the first survey since FDA head Marty Makary quit on 12 May. [11]

   Vinay Prasad, the FDA's head of biological medicines, left in April. [11]

   1. April Vinay Prasad leaves
   2. 12 May Marty Makary quits

   Why it matters

   Kyle Diamantas has run the FDA as acting head since May. [11]

   Heidi Overton, President Trump's pick to lead it, still awaits a US Senate committee vote. [11]

   How it works

   Survey researchers build such an index so 100 means neutral; below it, worriers outnumber the hopeful. [11]

   The truth

   • 40% of scientists asked expect the rules to get worse within a year. [11]
   • Only 12% of them expect things to improve. [11]
   • Nobody knows yet

     Who will lead the US drug regulator, and when.

     Heidi Overton still waits for a US Senate committee vote, and the US Senate is away until 9 November. [11]

   What comes next

   The US Senate is away until 9 November, after the midterm elections. [11]

8. 09

   Anthropic buys a one-person drug start-up

   What happened

   • Anthropic bought Mithril Medicine, a start-up that looks for new drugs. [12]
   • Mithril had one employee, who worked with AI tools and hired contractors. [12]
   • It was run by Cody Tranbarger, an entrepreneur-in-residence at the investor Atlas Venture. [12]
   • He posts on X under the name Professor Oak. [12]

   Who is involved

   Anthropic is the AI company that makes Claude. [13]

   • Anthropic AI company, the buyer
   • Mithril Medicine drug start-up
   • Cody Tranbarger ran Mithril
   • Novo Nordisk
   • Bristol Myers Squibb

   How it unfolded

   In its share-sale filing on 26 October, Anthropic said it is building its own biology lab. [13]

   Anthropic already works with the drugmakers Novo Nordisk and Bristol Myers Squibb. [13]

   Why it matters

   Endpoints News asked whether drug start-ups will soon run with one employee or none. [12]

   How it works

   In business terms, Mithril outsourced: it used hired contractors instead of its own staff. [12]

   The truth

   • Anthropic's filing says drug development brings scientific, regulatory and operational challenges beyond its software business. [13]
   • Who gains Anthropic — Buying Mithril adds a drug-hunting start-up to the biology lab it says it is building. [12][13]
9. 10

   Pakistan puts 86,000 medicines on a scan check

   What happened

   • Pakistan has registered over 86,000 medicines on its Track and Trace System. [14]
   • A phone scan of a pack shows buyers its price and whether it is genuine. [14]
   • Registering a medicine once took years; it now takes 21 days, he said. [14]

   Who is involved

   Health Minister Mustafa Kamal gave the figures in Karachi on Saturday. [14]

   • Mustafa Kamal Pakistan's health minister
   • Drugmakers want higher prices
   • Pakistan's government still deciding

   How it unfolded

   The Drug Regulatory Authority of Pakistan has handled over 5,000 cases since going digital. [14]

   Why it matters

   Drugmakers want to raise medicine prices, and Pakistan's government is still considering it. [14]

   How it works

   A phone scan that checks a pack is genuine helps buyers spot fake medicines. [14]

   The truth

   • Kamal said pricing 'requires serious attention'; the price request is still under consideration. [14]
   • Who gains People buying medicines in Pakistan — With a phone scan they can now check a pack's price and whether it is real. [14]
   • Nobody knows yet

     Whether Pakistan will let medicine prices rise.

     Drugmakers have asked for higher prices, and the health minister says the matter is still under consideration. [14]

10. 11

    A map of DNA tags in lung cancer

    What happened

    • Scientists in Poland mapped chemical tags on the DNA of lung cancers from 130 patients. [15]
    • They read 260 lung samples in all, published in Communications Biology on 1 November. [15]
    • Tags were missing from genes known to drive lung cancer. [15]
    • Tags were also lost at switches for small RNA genes linked to cancer spread. [15]
    • Some are linked to PD-L1, a protein tumours use to hide from immune cells. [15]
    • The two main kinds of lung cancer showed different patterns of tags. [15]

    Who is involved

    The team is at the Medical University of Bialystok, in Poland. [15]

    The tags are methylation marks, which help switch genes on or off without changing them. [15]

    • Medical University of Bialystok Poland

    Why it matters

    The authors say these changes may help explain why some lung cancers resist treatment. [15]

    How it works

    Epigenetics is the study of tags like these, which change how genes are used. [15]

    The truth

    • This is a map from tissue samples; it does not test any treatment. [15]
    • The authors report no competing interests; Poland's National Centre for Research and Development paid. [15]
11. 12

    Mesothelioma's tiny packages turn nearby cells into helpers

    What happened

    • Researchers in Sydney found how pleural mesothelioma, a lung-lining cancer, turns nearby cells into helpers. [16]
    • The cancer cells release tiny packages, called vesicles, that carry small RNA messages. [16]
    • The data suggest the packages carry more cancer-promoting messages and fewer cancer-blocking ones. [16]
    • In the lab, fibroblasts, the support cells around a tumour, took in the packages. [16]
    • The fibroblasts turned inflamed and began helping the cancer cells move and multiply. [16]

    Who is involved

    The team is at Sydney's Asbestos and Dust Diseases Research Institute and the University of Sydney. [16]

    Pleural mesothelioma is an aggressive cancer with a low survival rate, the authors write. [16]

    • Asbestos and Dust Diseases Research Institute Sydney
    • University of Sydney Australia
    • Fibroblasts support cells around a tumour

    Why it matters

    The authors say the messages could help doctors tell the cancer's two main types apart. [16]

    How it works

    Cancer biologists call a tumour's neighbouring cells its microenvironment, which it can change to help itself. [16]

    The truth

    • The work used cells in a dish and stored tissue samples; no patient was treated. [16]
    • A grant from the Dust Diseases Board paid for the work. [16]